The present invention relates to the crystal form A of a compound. The present invention further discloses a preparation method and a pharmaceutical composition of the crystal form A of the compound. The crystal form A has a relative strong hypoglycemic activity in vivo, and is hoped to be a new pharmaceutically active ingredient for treating or preventing type II diabetes and/or the complications of type II diabetes.